the effect of febuxostat in sepsis

Evaluating the effect of febuxostat drug administration compared to placebo in septic patients hospitalized in the intensive care unit

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230814059148N1

Enrollment

Registered

2023-10-10

Start date

2023-11-22

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis.

Interventions

Intervention 1: Intervention group: Receive 80 mg febuxostat tablets for 10 days, one tablet daily. Intervention 2: Control group: placebo.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Septic patients who are hospitalized in the intensive care unit

Exclusion criteria

Exclusion criteria: Patients taking Azathioprine, Mercaptopurine, or Methotrexate at the same time Patients with sensitivity to Febuxostat or Allopurinol or Lactose or any component of the formulation of these drugs Patients with severe liver failure class C (ALT >3×ULN and total serum bilirubin more than 2×ULN) Patients with malignancy Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
Interleukin 6 (IL-6) plasma level. Timepoint: Day 0 (before the start) and day 4 of the study. Method of measurement: ELISA kit for detection of interleukin 6 serum level.	—

Secondary

Measure	Time frame
The state of organ failure in sepsis. Timepoint: Days 0, 3, 7, 10. Method of measurement: Sequential Organ Failure Assessment (SOFA) Score.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaman Chaparzade

Tabriz University of Medical Sciences

chaparzade.sam@gmail.com+98 41 3382 8154

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026